ACTRN12611001024932招募中3 期
Prospectively evaluating, in high-risk prostate cancer patients, the utility of a patient decision aid for participation in the RAVES (Radiotherapy - Adjuvant Versus Early Salvage) trial (NCT00860652; TROG 08.03), compared to patients not receiving this intervention, in relation to rates of recruitment and decision-making outcomes.
Psycho-Oncology Cooperative Research Group (PoCoG)0 个研究点目标入组 150 人开始时间: 2011年9月26日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Educational / counselling / training
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Male
入选标准
- •Consenting men who are eligible to participate in RAVES (TROG 08.03): men with prostate cancer who have positive margins and/or stage pT3 disease following radical prostatectomy, aged over 18 years.
排除标准
- •Insufficient English to read the DA booklet and complete questionnaires, and severe psychiatric or cognitive disorders. Ineligibility to the RAVES trial implies exclusion to the DA study.
研究者
相似试验
撤回
不适用
Towards optimal treatment for high risk prostate cancer; stereotactic pelvic radiotherapy with focal boost to the primary tumorprostate cancerNL-OMON56376Haaglanden Medisch Centrum228
已完成
不适用
Individual risk assessment for prostate cancer: an impact analysis.Prostate carcinoma1003858810036958prostate cancerNL-OMON35373Erasmus MC, Universitair Medisch Centrum Rotterdam650
进行中（未招募）
不适用
Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate CancerProstate CancerNCT02302105Tata Memorial Centre224
进行中（未招募）
1 期
18F-FACBC PET/CT FOR STAGING HIGH RISK PROSTATE CANCERPatients affected by moderate to high risk primary prostate cancer who are scheduled for surgery with a planned, elective lymph node dissectionMedDRA version: 17.0Level: LLTClassification code 10036946Term: Prostatic cancerSystem Organ Class: 100000004864EUCTR2014-003165-15-ITAOU di Bologna Policlinico S.Orsola-Malpighi110
招募中
1 期
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 TrialProstate cancerCTIS2022-501551-90-00Gasthuiszusters Antwerpen493